What radiotherapy technique and dose are recommended for treating retinoblastoma?

Radiotherapy for Retinoblastoma: Technique and Dose Recommendations

For retinoblastoma requiring external beam radiotherapy, the standard dose is 45 Gy delivered in 1.5-2.0 Gy fractions, with modern techniques favoring focal stereotactic radiotherapy (40 Gy in 20 fractions) for posterior pole tumors or intensity-modulated radiotherapy (IMRT)/volumetric arc therapy (VMAT) for whole-eye treatment to minimize orbital bone and brain exposure.

Critical Context: Radiotherapy's Evolving Role

External beam radiotherapy is no longer first-line treatment for retinoblastoma due to the significant risk of subsequent malignant neoplasms, particularly sarcomas and CNS tumors in children with germline RB1 mutations 1. Modern management prioritizes chemotherapy with focal ablative therapy. However, radiotherapy remains valuable for recalcitrant disease not responding to other treatments 2.

Dose Recommendations by Clinical Scenario

Standard External Beam Radiotherapy

For Groups I-II (Reese-Ellsworth) or tumors ≤15 mm:

• Dose: 45 Gy in 1.5-2.0 Gy fractions 3
• This achieves 78.5% local control with external beam alone
• Additional 29.5% salvage possible with focal therapies
• Alternative regimen: 45 Gy in 15 fractions of 3 Gy, 3 times weekly 4

For Groups III-V or tumors >15 mm:

• Higher doses may be required (>45 Gy) 3
• Local control drops to only 20% with standard 45 Gy
• Consider alternative approaches first given poor outcomes

Focal Stereotactic Radiotherapy (Preferred Modern Approach)

For posterior pole (peripapillary/perimacular) tumors:

• Dose: 40 Gy in 20 fractions of 2 Gy daily 5
• Achieves complete response in 80% of focal tumors
• Dramatically reduces dose to critical structures:
  • Optic chiasm: median 0.25 Gy
  • Brainstem: median 0.07 Gy
  • Ipsilateral lens: median 3.74 Gy
  • Globe: median 19.11 Gy

Optimal Radiotherapy Techniques

Technique Selection Algorithm

First choice for focal posterior tumors:

• Focal stereotactic radiotherapy with image guidance 5
• Provides vision-sparing treatment with minimal toxicity

For whole-eye treatment (when required):

1. VMAT or helical tomotherapy - Best conformity index (1.3), lowest ipsilateral orbital bone V20Gy (56%), superior brain sparing 6
2. Nine-field IMRT - Similar conformity to VMAT, allows dose reduction to orbit and lacrimal gland while maintaining therapeutic dose to ora serrata 7
3. Electron beam techniques - Superior brain sparing, deliver approximately one-third the integral dose of photon techniques, but higher PTV dose gradient 6

Avoid:

• Traditional wedge pair techniques - Poor conformity (CI = 1.8), highest orbital bone exposure (V20Gy = 90%) 6
• Three-dimensional conformal radiotherapy alone - Inferior to IMRT/VMAT for normal tissue sparing

Critical Technical Considerations

Field Design Requirements

The ora serrata retinae must receive full therapeutic dose - this is a common failure point with inadequate field design 7. IMRT techniques and specific historical techniques (Haye, Cassady, Cormack, al-Beteri) successfully achieve this 7.

Lens Sparing

Cataract formation is directly related to dose to the lens germinal epithelium:

• Minimum cataractogenic dose: 8 Gy 4
• Cataracts develop when >1 mm of posterior lens is included in treatment field
• Modern focal techniques reduce lens dose to median 3.74 Gy 5

Pattern of Failure Analysis

External beam radiotherapy does NOT prevent new tumors in uninvolved retina 3. When analyzing 28 failure sites:

• 39% were new tumors in previously uninvolved retina
• 36% were recurrences from existing tumors
• 25% were vitreous seed progression

This challenges the traditional belief in "prophylactic" retinal treatment and supports focal therapy when feasible 3.

Treatment Decision Framework

When radiotherapy is indicated (recalcitrant disease after chemotherapy/focal therapy failure):

1. Assess tumor location and extent:

   • Posterior pole focal tumor → Focal stereotactic RT (40 Gy/20 fx)
   • Multiple tumors or vitreous seeding → Whole-eye VMAT/IMRT (45 Gy/1.5-2 Gy fx)
   • Groups I-II or ≤15 mm → Standard 45 Gy adequate
   • Groups III-V or >15 mm → Consider higher doses or alternative approaches

2. Prioritize technique based on available technology:

   • Image-guided VMAT/tomotherapy if available
   • Nine-field IMRT as alternative
   • Electron beams for brain sparing if photon IMRT unavailable

3. Critical structure dose constraints:

   • Lens: <8 Gy to prevent cataract
   • Optic chiasm: <0.5 Gy with focal techniques
   • Minimize orbital bone V20Gy (<60% with modern techniques)

Long-term Morbidity Considerations

The decision to use radiotherapy must weigh immediate tumor control against lifetime SMN risk 1. Survivors with germline RB1 mutations who received external beam radiotherapy have dramatically elevated risks of:

• Bone and soft tissue sarcomas
• CNS tumors (radiotherapy-related)
• Melanomas
• Uterine leiomyosarcoma

This mortality risk makes radiotherapy a last-resort option in the modern era, reserved for situations where globe salvage is otherwise impossible 2, 8.